ArticleExploratory research in clinical and social pharmacy2026
Evaluating patient acceptability of clinical pharmacist engagement following clinical decision support.
Article in Exploratory research in clinical and social pharmacy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: While Direct Oral Anticoagulant (DOAC) medications like apixaban and rivaroxaban have overtaken warfarin as first-line therapy for atrial fibrillation (AF) and venous thromboembolism (VTE), 10-20% of DOAC prescriptions deviate from the United States Food and Drug Administration (FDA) evidence-based package label instructions. To improve prescribing, we implemented electronic health record (EHR) alerts that encourage collaboration between prescribers and anticoagulation clinic pharmacists. Objective: This study investigates patients' acceptance and perceptions of outreach from anticoagulation pharmacists with whom they may not have preexisting relationships. Methods: We administered a 10-item structured questionnaire to 30 patients (or caregivers as proxies) who had received DOAC dosing recommendations directly from pharmacists following an EHR-based prescribing alert. The first 20 participants also answered open-ended interview questions. Mean scores were calculated for structured acceptability questions on a 5-point Likert scale. Interview transcripts were analyzed to identify facilitators and barriers to acceptance of pharmacist involvement in DOAC management. We also assessed alignment between quantitative and qualitative data. Results: Overall, patients found direct pharmacist outreach acceptable (mean acceptability score: 4.3, SD 0.15). Facilitators included pharmacists' expertise, clear communication, and friendly demeanor. Barriers included a perceived limit to pharmacists' prescribing authority and the timing of the advice. Pharmacists may mitigate these barriers by emphasizing that patients' doctors endorse the dosing recommendations and offering to answer additional questions at the end of calls. Conclusions: Anticoagulation pharmacists' direct outreach to patients can be valuable for DOAC management and is generally well-accepted. Addressing role confusion could further facilitate their direct patient contact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.